Suppr超能文献

再灌注时通过腺苷A2受体激活实现心脏保护。

Cardioprotection with adenosine A2 receptor activation at reperfusion.

作者信息

Xu Zhelong, Mueller Robert A, Park Sung-Sik, Boysen Philip G, Cohen Michael V, Downey James M

机构信息

Department of Anesthesiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

出版信息

J Cardiovasc Pharmacol. 2005 Dec;46(6):794-802. doi: 10.1097/01.fjc.0000188161.57018.29.

Abstract

Pre-ischemic treatment is seldom possible in the clinical setting of acute myocardial infarction. Thus, to successfully save myocardium from infarction, it is required that protective interventions must be effective when applied after ischemia has begun or at the onset of reperfusion. Unfortunately, in spite of a large body of experimental data showing that various interventions are cardioprotective at reperfusion, no specific therapy has yet been established to be clinically applicable. However, recent data from several laboratories have shown that adenosine and its analogues given at reperfusion can markedly protect the heart from ischemia/reperfusion injury. While the experimental data suggest that factors such as adenosine A2 receptor activation, anti-neutrophil effect, attenuation of free radical generation, increased nitric oxide (NO) availability, activation of the PI3-kinase/Akt pathway and ERK, prevention of mitochondrial damage, and anti-apoptotic effects may be involved in the protective effect of adenosine or its analogues, the exact receptor subtype(s), the detailed signaling mechanisms, and interaction between those individual factors are still unknown. A definite answer to these unsolved problems will offer insights into the mechanisms of cardioprotection at reperfusion, and will be critical for developing a successful therapeutic strategy to salvage ischemic myocardium in patients with acute myocardial infarction.

摘要

在急性心肌梗死的临床环境中,缺血前治疗很少可行。因此,为了成功地使心肌免于梗死,要求保护干预措施在缺血开始后或再灌注开始时应用时必须有效。不幸的是,尽管大量实验数据表明各种干预措施在再灌注时具有心脏保护作用,但尚未确立任何可临床应用的特异性治疗方法。然而,几个实验室最近的数据表明,在再灌注时给予腺苷及其类似物可显著保护心脏免受缺血/再灌注损伤。虽然实验数据表明,腺苷A2受体激活、抗中性粒细胞作用、自由基生成减少、一氧化氮(NO)可用性增加、PI3激酶/Akt途径和ERK激活、线粒体损伤预防以及抗凋亡作用等因素可能参与腺苷或其类似物的保护作用,但确切的受体亚型、详细的信号传导机制以及这些个体因素之间的相互作用仍然未知。对这些未解决问题的明确答案将为再灌注时的心脏保护机制提供见解,并且对于制定成功的治疗策略以挽救急性心肌梗死患者的缺血心肌至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验